Wang G X, Wang L, Zhao Z Z, Tao P Z, Wang S Q
Institute of Materia Medica, Beijing.
Yao Xue Xue Bao. 1996;31(11):831-6.
Tai-Ding-An (3-phthalimido-2-oxo-n-butyraldehyde bisthiosemicarbazone, TDA) is an antiviral drug first synthesized in this institute. In order to clarify the difference between the two enantiomeric isomers of TDA, (R)- and (S)-TDA were synthesized from (R)- and (S)-alanine, respectively, via the following steps: fusing with phthalic anhydride gave 2-phthalimido alanine(2a or 2b). The resulting acid was reacted with thionyl chloride to offer the corresponding acid chloride(3a or 3b), which was treated with diazomethane to give the diazoketone(4a or 4b). Bromination of the ketone with hydrobromic acid gave the key intermediate 3-phthalimido-2-oxo-1-bromobutanone (5a or 5b). Compound 5a or 5b was oxidized with DMSO to give 6a or 6b, which was directly condensed with thiosemicarbazide to afford the desired (R)- or (S)-TDA. (R)-TDA, (S)-TDA and (RS)-TDA have been tested in cell culture for anti-Herpes simplex virus I (HSV-1) and HSV-2 activities by plaque reducing method. All of them showed inhibitory effects on HSV-1 and HSV-2 replication with IC50 of 0.0296 mmol.L-1, 0.0359 mmol.L-1 and 0.0418 mmol.L-1 for HSV-1 and 0.88 mmol.L-1, 1.04 mmol.L-1 and 1.06 mmol.L-1 for HSV-2. Not much difference was found among these compounds either on IC50 or on therapeutic indexes.
泰定安(3-邻苯二甲酰亚氨基-2-氧代正丁醛双硫代半卡巴腙,TDA)是本研究所首次合成的一种抗病毒药物。为了阐明TDA两种对映体异构体之间的差异,分别通过以下步骤从(R)-和(S)-丙氨酸合成了(R)-TDA和(S)-TDA:与邻苯二甲酸酐熔融得到2-邻苯二甲酰亚氨基丙氨酸(2a或2b)。所得酸与亚硫酰氯反应得到相应的酰氯(3a或3b),酰氯用重氮甲烷处理得到重氮酮(4a或4b)。用氢溴酸将酮溴化得到关键中间体3-邻苯二甲酰亚氨基-2-氧代-1-溴丁酮(5a或5b)。化合物5a或5b用二甲基亚砜氧化得到6a或6b,6a或6b直接与硫代半卡巴腙缩合得到所需的(R)-或(S)-TDA。已通过噬斑减少法在细胞培养中测试了(R)-TDA、(S)-TDA和(RS)-TDA对单纯疱疹病毒I(HSV-1)和HSV-2的抗病毒活性。它们均对HSV-1和HSV-2的复制表现出抑制作用,对HSV-1的IC50分别为0.0296 mmol·L-1、0.0359 mmol·L-1和0.0418 mmol·L-1,对HSV-2的IC50分别为0.88 mmol·L-1、1.04 mmol·L-1和1.06 mmol·L-1。这些化合物在IC50或治疗指数方面均未发现太大差异。